NASDAQ:ONCY Oncolytics Biotech Q1 2026 Earnings Report $0.80 -0.01 (-1.24%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$0.82 +0.03 (+3.27%) As of 09/9/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncolytics Biotech EPS ResultsActual EPS-$0.08Consensus EPS -$0.05Beat/MissMissed by -$0.03One Year Ago EPSN/AOncolytics Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncolytics Biotech Announcement DetailsQuarterQ1 2026Date5/14/2026TimeAfter Market ClosesConference Call DateThursday, May 14, 2026Conference Call Time4:00PM ETUpcoming EarningsOncolytics Biotech's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Oncolytics Biotech Earnings HeadlinesZacks Research Has Negative Outlook of ONCY FY2026 EarningsSeptember 4, 2026 | americanbankingnews.comOncolytics Biotech gains FDA alignment on REO 033 trialAugust 20, 2026 | theglobeandmail.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal CancerAugust 18, 2026 | globenewswire.comOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal CancerJuly 20, 2026 | globenewswire.comONCY: Seeking Registration Pathway for Part B of REO 033 TrialJuly 16, 2026 | finance.yahoo.comSee More Oncolytics Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email. Email Address About Oncolytics BiotechOncolytics Biotech (NASDAQ:ONCY) (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors. Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers. Collaborations with academic centers and pharmaceutical partners support ongoing research into optimal dosing regimens, novel combination strategies and biomarker identification. The company also maintains an early-stage pipeline of additional viral candidates aimed at broadening its platform of immune‐activating cancer therapies. Headquartered in Calgary, Alberta, with a research and development facility in Houston, Texas, Oncolytics sustains a presence in major North American life science hubs. The company’s infrastructure supports integrated translational research, process development and global clinical trial management, with a focus on advancing regulatory filings and securing strategic partnerships to accelerate commercialization. Under the leadership of President and Chief Executive Officer Brad Thompson, Oncolytics’ management team brings extensive experience in oncology drug development, virology and biopharmaceutical operations. The company remains committed to advancing its viral immunotherapy platform through rigorous clinical investigation and collaborative programs designed to address unmet needs in oncology.View Oncolytics Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality RetailerCathie Wood Trimmed Palantir, But the Bigger Story Is Still ValuationIntel’s ASML Milestone Gives Investors a New Reason to Revisit the StockAnalog Devices Shows Why AI Is Not the Only Story Driving Chip DemandDefense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy RiskLithia’s Record Quarter Keeps the Bull Case AliveLululemon’s Problems May Not Be a Warning for Every Athleticwear Stock Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
